Advances in prevention of respiratory syncytial virus infections

Journal of Pediatrics

Volumn 135, Issue 5, 1999, Pages 546-558

  Prober, C G ^a   Sullender, W M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VACCINATION; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS;

EID: 0033504290     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70051-X     Document Type: Article

References (134)

1. JA Morris RE Blount RE. Savage Recovery of cytopathic agent from chimpanzees with coryza Proc Soc Exp Biol Med 92 1956 544 549
2. M Beem RH Wright D Hamre R Egerer M. Oehme Association of the chimpanzee coryza agent with acute respiratory disease in children N Engl J Med 263 1960 523 530
3. RM Chanock L. Finberg Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children Am J Hyg 66 1957 291 300
4. LJ Anderson JC Hierholzer C Tsou RM Hendry BF Fernie Y Stone Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies J Infect Dis 151 1985 626 633
5. PR Johnson MK Spriggs RA Olmsted PL. Collins The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins Proc Natl Acad Sci USA 84 1987 5625 5629
6. RM Hendry AL Talis E Godfrey LJ Anderson BF Fernie K. McIntosh Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks J Infect Dis 153 1986 291 297
7. PL Collins K McIntosh RM. Chanock Respiratory syncytial virus 3rd ed BN Fields DM Knipe PM Howley Fields virology. 1996 Lippincott-Raven Philadelphia 1313 1351
8. E Domingo JJ. Holland Mutation rates and rapid evolution of RNA viruses SS Morse The evolutionary biology of viruses. 1994 Raven Press New York 161 184
9. B Garcia-Barreno C Palomo C Penas T Delgado P Perez-Brena JA. Melero Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins J Virol 63 1989 925 932
10. SR Roberts RW Compans GW. Wertz Respiratory syncytial virus matures at the apical surfaces of polarized epithelial cells J Virol 69 1995 2667 2673
11. PA Cane DA Matthews CR. Pringle Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses J Gen Virol 72 1991 2091 2096
12. PR Johnson MK Spriggs RA Olmsted PL. Collins The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins Proc Natl Acad Sci USA 84 1987 5625 5629
13. WM Sullender LJ Anderson MA Mufson GW. Wertz Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses J Virol 65 1991 5425 5434
14. JA Lopez R Bustos C Orvell M Berois J Arbiza B Garcia-Barreno Antigenic structure of human respiratory syncytial virus fusion glycoprotein J Virol 72 1998 6922 6928
15. DJ Plows CR. Pringle Variation in the fusion glycoprotein gene of human respiratory syncytial virus subgroup A Virus Genes 11 1995 37 45
16. MA Mufson RB Belshe C Orvell E. Norrby Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections J Clin Microbiol 25 1987 1535 1539
17. RG Webster WG Laver GM Air GC. Schild Molecular mechanisms of variation in influenza viruses Nature 296 1982 115 121
18. WM Sullender MA Mufson GA Prince LJ Anderson GW. Wertz Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial virus that have caused repeat infection in children J Infect Dis 178 1998 925 932
19. CB Hall EE Walsh CE Long KC. Schnabel Immunity to and frequency of reinfection with respiratory syncytial virus J Infect Dis 163 1991 693 698
20. MS Hirsch JC Kaplan RT. D’Aquila Antiviral agents 3rd ed BN Fields DM Knipe PM Howley Fields virology. 1996 Lippincott-Raven Philadelphia 431 466
21. S Levine R Klaiber-Franco PR. Paradiso Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus J Gen Virol 68 1987 2521 2524
22. EE Walsh MW Brandriss JJ. Schlesinger Purification and characterization of the respiratory syncytial virus fusion protein J Gen Virol 66 1985 409 415
23. PR. Wyde Respiratory syncytial virus (RSV) disease and prospects for its control Antiviral Res 39 1998 63 79
24. PL Collins MG Hill E Camargo H Grosfeld RM Chanock BR. Murphy Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading from of the M2 mRNA in gene expression and provides a capability for vaccine development Proc Natl Acad Sci USA 92 1995 11563 11567
25. RW Hardy GW. Wertz The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription J Virol 72 1998 520 526
26. PL Atreya ME Peeples PL. Collins The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication J Virol 72 1998 1452 1461
27. W Aherne T Bird SDM Court PS Gardner J. McQuillin Pathological changes in virus infections of the lower respiratory tract in children J Clin Pathol 23 1970 7 18
28. JV Mills JE Van Kirk PF Wright RM. Chanock Experimental respiratory syncytial virus infection of adults J Immunol 107 1971 123 130
29. JA Englund CJ Sullivan C Jordan LP Dehner GM Vercellotti HH. Balfour Respiratory syncytial virus infection in immunocompromised adults Ann Intern Med 109 1988 203 208
30. M Fishaut D Tubergen K. McIntosh Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity J Pediatr 96 1980 179 186
31. CB Hall KR Powell NE MacDonald CL Gala ME Menegus SC Suffin Respiratory syncytial viral infection in children with compromised immune function N Engl J Med 315 1986 77 81
32. MJ Cannon PJM Openshaw BA. Askonas Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus J Exp Med 168 1988 1163 1168
33. BS Graham LA Bunton PF Wright DT. Karzon Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice J Clin Invest 88 1991 1026 1033
34. WH Alwan FM Record PJM. Openshaw CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells Clin Exp Immunol 88 1992 527 536
35. BS. Graham Pathogenesis of respiratory syncytial virus vaccine-augmented pathology Am J Respir Crit Care Med 152 1995 S63 S66
36. BS Graham LA Bunton J Rowland PF Wright DT. Karzon Respiratory syncytial virus infection in anti-mu-treated mice J Virol 65 1991 4936 4942
37. AK Abbas KM Murphy A. Sher Functional diversity of helper T lymphocytes Nature 383 1996 787 793
38. BS Graham GS Henderson YW Tang X Lu KM Neuzil DG. Colley Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus J Immunol 151 1993 2032 2040
39. PJM Openshaw SL Clarke FM. Record Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G Int Immunol 4 1992 493 500
40. ME Waris C Tsou DD Erdman SR Zaki LJ. Anderson Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern J Virol 70 1996 2852 2860
41. CRM Bangham PJM Openshaw LA Ball AMQ King GW Wertz BA. Askonas Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants J Immunol 137 1986 3973 3977
42. HW Kim SL Leikin J Arrobio CD Brandt RM Chanock RH. Parrott Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection Pediatr Res 10 1976 75 78
43. S Becker J Soukup JR. Yankaskas Respiratory syncytial virus infection of human primary nasal and bronchial epithelial cell cultures and bronchoalveolar macrophages Am J Respir Cell Mol Biol 6 1992 369 374
44. TL Noah FW Henderson IA Wortman RB Devlin J Handy HS Koren Nasal cytokine production in viral acute upper respiratory infection of childhood J Infect Dis 171 1995 584 592
45. B Olszewska-Pazdrak A Casola T Saito R Alam SE Crowe F Mei Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus J Virol 72 1998 4756 4764
46. BS. Graham Immunological determinants of disease caused by respiratory syncytial virus Trends Microbiol 4 1996 290 293
47. BJ. Selwyn The epidemiology of acute respiratory tract infections in young children: comparison of findings from several developing countries Rev Infect Dis 12 suppl 8 1990 S870 S888
48. LJ Anderson RA Parker RL. Strikas Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children J Infect Dis 161 1990 640 646
49. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development Prospects for immunizing against respiratory syncytial virus. New vaccine development, establishing priorities vol 1 1988 National Academy of Sciences Press Washington (DC) 397 409
50. L Navas E Wang V de Carvalho J. Robinson Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children J Pediatr 121 1992 348 354
51. RC. Welliver Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection Semin Perinatol 22 1998 87 95
52. American Academy of Pediatrics Respiratory syncytial virus 24th ed G Peter 1997 Redbook: report of the Committee on Infectious Diseases. 1997 American Academy of Pediatrics Elk Grove Village (IL) 443 447
53. WP Glezen LH Taber AL Frank JA. Kasel Risk of primary infection and reinfection with respiratory syncytial virus Am J Dis Child 140 1986 543 546
54. RC Welliver DT Wong M Sun E Middleton Jr RS Vaughan PL. Ogra The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection N Engl J Med 305 1981 841 846
55. N Sigurs R Bjarnason F Sigurbergsson B Kjellman B. Bjorksten Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls Pediatrics 95 1995 500 505
56. CL Lamprecht HE Klause MA. Mufson Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus J Infect Dis 134 1976 211 217
57. WP Glezen A Paredes JE Allison LH Taber AL. Frank Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level J Pediatr 98 1981 708 715
58. FW Henderson AM Collier WA Clyde FW. Denny Respiratory-syncytial-virus infections, reinfections, and immunity: a prospective longitudinal study in young infants N Engl J Med 300 1979 530 534
59. EEL Wang BJ Law JL Robinson S Dobson S al Jumaah D Stephens PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on RSV illness in patients with underlying heart or lung disease Pediatrics 99 3 1997 E9
60. SC Suffin GA Prince KB Muck DD. Porter Immunoprophylaxis of respiratory syncytial virus in the infant ferret J Immunol 123 1979 10 14
61. GA Prince VG Hemming RI Horswoog RM. Chanock Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat Virus Res 3 1985 193 206
62. GR Siber RD Leombruno J Leszczynski J McIver D Bodkin R Gonin Comparisons of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin J Infect Dis 169 1994 1368 1373
63. HC Meissner DR Fulton JR Groothuis RL Geggel GR Marx VG Hemming Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin Antimicrob Agents Chemother 37 1993 1655 1658
64. JR Groothuis EAF Simoes JJ Levin CB Hall CE Long WJ Rodriguez Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children N Engl J Med 329 1993 1524 1530
65. PREVENT Study Group Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis Pediatrics 99 1997 93 99
66. EAF Simoes HM Sondheimer FH Top HC Meissner RC Welliver AA Kramer Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease J Pediatr 133 1998 492 499
67. EAF Simoes JR Groothuis DA Tristram K Ailessi MV Lehr GR Siber Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children J Pediatr 129 1996 214 219
68. JW Hay RL Ernst HC. Meissner Respiratory syncytial virus immune globulin: a cost-effectiveness analysis Am J Managed Care 2 1996 841 856
69. TM O’Shea MA Sevick LB. Givner Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants Pediatr Infect Dis J 17 1998 587 593
70. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Respiratory syncytial virus immune globulin intravenous: indications for use Pediatrics 99 1997 645 650
71. EE Walsh JJ Schlesinger MW. Brandes Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies Infect Immun 43 1984 736 738
72. S Johnson C Oliver GA Prince VG Hemming DS Pfarr SC Wang Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus (RSV) J Infect Dis 176 1997 1215 1224
73. JA Beeler K. van Wyke Coelingh Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function J Virol 63 1989 2941 2950
74. X Saez-Llorens E Castano D Null J Steichen PJ Sanchez O Ramilo Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia Pediatr Infect Dis J 17 1998 787 791
75. IMpact-RSV Study Group Palvizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 1998 531 537
76. FW Moler RW Brown RG Faix JR. Gilsdorf Comments on palivivizumab (Synagis) Pediatrics 103 1999 495 497
77. GA. Storch Humanized monoclonal antibody for prevention of respiratory syncytial virus infection Pediatrics 102 1998 648 651
78. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV Pediatrics 102 1998 1211 1216
79. HC Meissner RC Welliver SA Chartrand DR Fulton WJA Rodriguez JR. Groothuis Prevention of respiratory syncytial virus infection in high risk infants. Consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin Pediatr Infect Dis J 15 1996 1059 1068
80. K Kristensen A Gyhrs B Lausen T Barington C. Heilmann Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants Pediatr Infect Dis J 15 1996 525 529
81. BR Murphy PL. Collins Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum for a joint WHO/NIAID meeting WHO Bull OMS 75 1997 307 313
82. RA Dudas RA. Karron Respiratory syncytial virus vaccines Clin Microbiol Rev 11 1998 430 439
83. JE Crowe Jr PT Bui WT London AR Davis PP Hung RM Chanock Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis Vaccine 12 1994 691 699
84. JE Crowe PT Bui CY Firestone Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates J Infect Dis 173 1996 829 839
85. RA Karron PF Wright JE Crowe Jr Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children J Infect Dis 176 1997 1428 1436
86. CR Pringle AH Filipiuk BS Robinson PJ Watt P Higgins DAJ. Tyrrell Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers Vaccine 11 1993 473 478
87. VB Randolph M Kandis P Stemler-Higgins Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation Virus Res 33 1994 241 259
88. RA Karron DA Bounagurio AF Georgius Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant Proc Natl Acad Sci USA 94 1997 13961 13966
89. SS Whitehead CY Firestone RA Karron Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts 530/1030 to RSV vaccine candidate cpts 248/404 increases its attenuation and temperature sensitivity J Virol 73 1999 871 877
90. A Bukreyev E Camargo PL. Collins Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene J Virol 70 1996 6634 6641
91. H Jin D Clarke HZY Zhou Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV Virology 251 1998 206 214
92. EE Walsh CB Hall M Briselli MW Brandriss JJ. Schlesinger Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection J Infect Dis 155 1987 1198 1204
93. RB Belshe EL Anderson EE. Walsh Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children J Infect Dis 168 1993 1024 1029
94. J Englund WP Glezen PA. Piedra Maternal immunization against viral disease Vaccine 16 1998 1456 1463
95. JR Groothuis SJ King DA Hogerman PR Paradiso EA. Simoes Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia J Infect Dis 177 1998 467 469
96. PR Paradiso SW Hildreth DA Hogerman Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old Pediatr Infect Dis J 13 1994 792 798
97. PA Piedra S Grace A Jewell Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis Pediatr Infect Dis J 15 1996 23 31
98. DA Tristram RC Welliver CK Mohar DA Hogerman SW Hildreth P. Paradiso Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old J Infect Dis 167 1993 191 195
99. CA Siegrist H Plotnicky-Gilquin M Cordova M Berney JY Bonnefoy TN Nguyen Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies J Infect Dis 179 1999 1326 1333
100. PA Piedra S Grace A Jewell S Spinelli DA Hogerman F Malinoski Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis Pediatr Infect Dis J 17 1998 217 224
101. AR Falsey EE. Walsh Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60 Vaccine 14 1996 1214 1218
102. AR Falsey EE. Walsh Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly Vaccine 15 1997 1130 1132
103. MW Wathen RJ Brideau DR. Thomsen Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector J Infect Dis 159 1989 255 263
104. WM Sullender WJ. Britt Antigenic and immunogenic analysis of group A and group B respiratory syncytial virus G proteins expressed from recombinant baculoviruses J Gen Virol 77 1996 641 648
105. UF Power H Plotnicky-Gilquin T Huss Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment Virology 230 1997 155 166
106. EJ Stott G Taylor LA Ball Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus J Virol 61 1987 3855 3861
107. RS Schrijver JP Langedijk GM Keil Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV Vaccine 15 1997 1908 1916
108. X Li S Sambhara CX Li Protection against respiratory syncytial virus infection by DNA immunization J Exp Med 188 1998 681 688
109. M Trudel NC Seguin H. Binz Protection of Balb/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein Virology 185 1991 749 757
110. D Chargelegue OE Obeid SC Hsu MD Shaw AN Denbury G Taylor A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo J Virol 72 1998 2040 2046
111. PR Johnson RA Olmsted GA Prince BR Murphy DW Alling EE Walsh Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity J Virol 61 1987 3163 3166
112. MJ Schnell T Mebatsion KK. Conzelmann Infectious rabies viruses from cloned cDNA EMBO J 13 1994 4195 4203
113. A Roberts JK. Rose Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field Virology 247 1998 1 6
114. BR Murphy A Sotnikov LA Lawrence SM Banks GA. Prince Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization Vaccine 8 1990 497 502
115. W Hildreth RR Baggs DG Brownstein WL Castleman PR. Paradiso Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization Vaccine 11 1993 615 618
116. RM Hendry JC Burns EE Walsh Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus J Infect Dis 157 1988 640 647
117. RJ Brideau RR Walters MA Stier MW. Wathen Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein J Gen Virol 70 1989 2637 2644
118. AH Cherrie K Anderson GW Wertz PJM. Openshaw Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus J Virol 66 1992 2102 2110
119. KH Hsu MD Lubeck BM Bhat Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model Vaccine 12 1994 607 612
120. JB Ulmer JJ Donnelly SE Parker Heterologous protection against influenza by injection of DNA encoding a viral protein Science 259 1993 1745 1749
121. DE Hassett J Zhang JL. Whitton Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge J Virol 71 1997 7881 7888
122. WP. Glezen Pathogenesis of bronchiolitis—epidemiologic considerations Pediatr Res 11 1977 239 243
123. C Brandt UF Power H Plotnicky-Gilquin Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na J Infect Dis 176 1997 884 891
124. W Buraphacheep WM. Sullender The guinea pig as a model for the study of maternal immunization against respiratory syncytial virus infections in infancy J Infect Dis 175 1997 935 938
125. DA. Goldmann Nosocomial viral infections Recent developments and new strategies Eur J Clin Microbiol Infect Dis 8 1989 75 81
126. CB Hall RG Douglas JM. Geiman Respiratory syncytial virus infections in infants: quantitation and duration of shedding J Pediatr 89 1976 11 15
127. NE MacDonald CB Hall SC Suffin C Alexson PJ Harris JA. Manning Respiratory syncytial viral infection in infants with congenital heart disease N Engl J Med 307 1982 397 400
128. CB Hall RG. Douglas Nosocomial respiratory syncytial virus infections: Should gowns and masks be used? Am J Dis Child 135 1891 512 515
129. D Murphy JK Todd RK Chao I Orr K. McIntosh The use of gowns and masks to control respiratory illness in pediatric hospital personnel J Pediatr 99 1981 746 750
130. JM LeClair J Freeman BF Sullivan CM Crowley DA. Goldmann Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions N Engl J Med 317 1987 329 334
131. CL Gala CB Hall KC Schnabel PH Pincus P Blossom SW Hildreth The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection JAMA 256 1986 2706 2708
132. K Krasinski R LaCouture R Holzman E Waithe S Bonk B. Hanna Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission J Pediatr 116 1990 894 898
133. D Isaacs H Dickson C O’Callaghan R Sheaves A Winter E. Moxon Handwashing and cohorting in prevention of hospital acquired infections with respiratory syncytial virus Arch Dis Child 66 1991 227 231
134. P Madge J Paton J McColl P. Mackie Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus Lancet 340 1992 1079 1083